Is it 17a-methyl-5a-dehydro-etiocholane-4,6-dien-3-one-17-ol and in a red bottle? If so we did the label correction coming on 2 years ago. This is simply the 17a methyl analog of 17b-hydroxy-androsta-4,6-dien-3-one that started so much contraversy about a year or more ago. The issue was "is it an androgen or an AI?". Well, both as is teslac, aromasin ATD and most other AIs. However it sucks as a serious anabolic as even n higher dosages it fails to show up in total testosterone as an AAS should. Patrick Arnold and I do not agree that a methyl bond at 17a still allows for AI activity. Though I usually agree with PA this would be to say that Masterone has no AI value and that the lower estrogen levels blood work has shown durring testing were wrong as well. It also would mean that several journals and patent applications are in error. So is it an AI?
Well, hell yes...
A synopsis of the anti-aromatase (anti-estrogenic) capacity of 17b-hydroxy-androsta-4,6-dien-3-one and its preferential nature in this capacity over other agents
17b-hydroxy-androsta-4,6-dien-3-one is an anti-aromatase in the family of other ‘6-delta’ androstenes. The addition of a 6-delta (6-ene) group allows for any androstene to become predominantly anti-estrogenic by creating a compound that now potently induces anti-aromatase activity. In this family 3,17-diones (ie., androsta-1,4,6-trien-3,17-dione, androsta-4,6-dien-3,17-dione) are the most potent anti-aromatase agents in regard to the effect of the 3 and 17 position functional groups on activity. However, these agents appear to have a disposition to induce unwanted side effects which include gynecomastia. It has been found that 17-hydroxy-3-one agents still display a sound potent anti-aromatase capacity (though of a slightly lower potency than 3,17-diones), but do not appear to have any predisposition to unwanted negative side effects, particularly the highly unwanted potential for gynecomastia. Overall they are the preferred agents to allow the body to have optimized estrogen modulation without undesirable drawbacks. The 4,6-dien is preferred over the 1,4,6-trien analogue as simply it is superior still in overall cost effectiveness and thus the most superior commercial agent for the purpose of positive estrogen modulation.
Documentation that expounds on the nature of 17b-hydroxy-androsta-4,6-dien-3-one as well as related agents as an aromatase inhibitor (AI) can be found in the below reference:
A Schering patent that cites the compound as an AI and the reference it is within:
Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men - US Patent 6696432 (link to patent)
(excerpt)
For the purposes of this invention, aromatase inhibitors are all those compounds that prevent estrogens from being formed from their metabolic precursors by inhibiting the enzyme aromatase (inhibition of biosynthesis). As aromatase inhibitors, therefore, all compounds are suitable that are suitable as substrates for aromatase, such as, for example, the testolactone (17a-oxa-D-homoandrost-1,4-diene-3,17-dione) that is described in the "Journal of Clinical Endocrinology and Metabolism," 49, 672 (1979); the compounds that are described in "Endocrinology " 1973, Vol. 92, No. 3, page 874:
androsta-4,6-diene-3,17-dione,
androsta-4,6-dien-17beta-ol-3-one acetate,
androsta-1,4,6-triene-3,17-dione,
4-androstene-19-chloro-3,17-dione,
4-androstene-3,6,17-trione;
Again all androstene compounds will have a predominantly AI capacity if the 6-position is altered. Such alterations include the abovementioned 6-delta alteration, the commonly known 6-oxo alteration, as well as many others including alkylations, brominations, et. al. While 17-one compounds in this class have a higher AI potency they are unfavorable due to their inherent predisposition to cause unwanted effects. The 17-hydroxy variants are superior overall as to their strong AI potency that while slightly below 17-one agents do not have the potential for unwanted side effects found with their 17-one counterparts.
Make sense why we still believe in Jungle Warfare after all the bashing by other company reps? We have good research to support this but naturaly some idiot will call it otherwise.
